Historically, cancer treatment has been a continuous research achievement in the pharmaceutical sciences, yet significant challenges remain to be addressed. Among these challenges, high-grade neuroendocrine tumors, particularly malignancies such as small cell lung cancer (SCLC), have confronted persistent issues of recurrent relapse due to their rapid doubling time and high growth fraction. Conventional first-line platinum-based chemotherapy and immune checkpoint inhibitors provide only limited survival extension following initial response, with no distinct therapeutic options available after second-line treatment. These therapeutic limitations are associated with aberrant activation of signaling pathways related to the genetic and functional characteristics of SCLC, with Notch signal suppression and DLL3 overexpression being recognized as major molecular features. DLL3 is an inhibitory Notch ligand highly expressed in SCLC that is rarely expressed in normal tissues and appears selectively in tumor cells, making it an attractive therapeutic target. Recently, various therapeutic strategies targeting DLL3 have been developed, including antibody-drug conjugates, bispecific T cell engagers (BiTEs), and chimeric antigen receptor T cells. This review discusses the pathophysiology of SCLC and the role of DLL3, as well as the development process and clinical utility of DLL3-targeted immunotherapeutic strategies. Furthermore, we examine the latest research trends and developmental potential of BiTE-based immunotherapy centered on Tarlatamab among DLL3-targeted therapies.
- Open Access
- Review
Targeting DLL3 in Small Cell Lung Cancer: Therapeutic Strategies and the Emerging Role of Tarlatamab
- Yunhyeong Lee,
- Sun-Young Han *
Author Information
Received: 09 Aug 2025 | Revised: 01 Oct 2025 | Accepted: 25 Dec 2025 | Published: 31 Dec 2025
Abstract
Keywords
small cell lung cancer | notch signaling | delta-like ligand 3 | targeted therapy | bispecific T cell engagers | tarlatamab
References
- 1.
Cersosimo, R.J. Lung cancer: A review. Am. J. Health Syst. Pharm. 2002, 59, 611–642.
- 2.
Raso, M.G.; Bota-Rabassedas, N.; Wistuba, I.I. Pathology and Classification of SCLC. Cancers 2021, 13, 820.
- 3.
Wang, Q.; Gumus, Z.H.; Colarossi, C.; Memeo, L.; Wang, X.; Kong, C.Y.; Boffetta, P. SCLC: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening, and Early Detection. J. Thorac. Oncol. 2023, 18, 31–46.
- 4.
Garg, A.D.; Agostinis, P. Diversifying the platinum-based chemotherapy toolkit for immunogenic cancer cell death. Oncotarget 2020, 11, 3352–3353.
- 5.
Rossi, A.; Di Maio, M.; Chiodini, P.; Rudd, R.M.; Okamoto, H.; Skarlos, D.V.; Fruh, M.; Qian, W.; Tamura, T.; Samantas, E.; et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: The COCIS meta-analysis of individual patient data. J. Clin. Oncol. 2012, 30, 1692–1698.
- 6.
Zhou, J.; Kang, Y.; Chen, L.; Wang, H.; Liu, J.; Zeng, S.; Yu, L. The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents. Front. Pharmacol. 2020, 11, 343.
- 7.
de Jong, W.K.; ten Hacken, N.H.; Groen, H.J. Third-line chemotherapy for small cell lung cancer. Lung Cancer 2006, 52, 339–342.
- 8.
Quoix, E. Topotecan in the treatment of relapsed small cell lung cancer. Onco. Targets Ther. 2008, 1, 79–86.
- 9.
Shim, J.S.; Kim, Y.; Yuh, T.; Lee, J.B.; Kim, H.R.; Hong, M.H.; Cho, B.C.; Lim, S.M. Real-World Outcomes with Lurbinectedin in Second Line and Beyond for Extensive Stage Small Cell Lung Cancer in Korea. Lung Cancer 2024, 15, 149–159.
- 10.
Rudin, C.M.; Reck, M.; Johnson, M.L.; Blackhall, F.; Hann, C.L.; Yang, J.C.; Bailis, J.M.; Bebb, G.; Goldrick, A.; Umejiego, J.; et al. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer. J. Hematol. Oncol. 2023, 16, 66.
- 11.
George, J.; Lim, J.S.; Jang, S.J.; Cun, Y.; Ozretic, L.; Kong, G.; Leenders, F.; Lu, X.; Fernandez-Cuesta, L.; Bosco, G.; et al. Comprehensive genomic profiles of small cell lung cancer. Nature 2015, 524, 47–53.
- 12.
Metz, C.W.; Bridges, C.B. Incompatibility of Mutant Races in Drosophila. Proc. Natl. Acad. Sci. USA 1917, 3, 673–678.
- 13.
Artavanis-Tsakonas, S.; Muskavitch, M.A.; Yedvobnick, B. Molecular cloning of Notch, a locus affecting neurogenesis in Drosophila melanogaster. Proc. Natl. Acad. Sci. USA 1983, 80, 1977–1981.
- 14.
Ranganathan, P.; Weaver, K.L.; Capobianco, A.J. Notch signalling in solid tumours: A little bit of everything but not all the time. Nat. Rev. Cancer 2011, 11, 338–351.
- 15.
Kopan, R.; Ilagan, M.X. The canonical Notch signaling pathway: Unfolding the activation mechanism. Cell 2009, 137, 216–233.
- 16.
Shi, Q.; Xue, C.; Zeng, Y.; Yuan, X.; Chu, Q.; Jiang, S.; Wang, J.; Zhang, Y.; Zhu, D.; Li, L. Notch signaling pathway in cancer: From mechanistic insights to targeted therapies. Signal Transduct. Target. Ther. 2024, 9, 128.
- 17.
Kovall, R.A.; Gebelein, B.; Sprinzak, D.; Kopan, R. The Canonical Notch Signaling Pathway: Structural and Biochemical Insights into Shape, Sugar, and Force. Dev. Cell 2017, 41, 228–241.
- 18.
Ellisen, L.W.; Bird, J.; West, D.C.; Soreng, A.L.; Reynolds, T.C.; Smith, S.D.; Sklar, J. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991, 66, 649–661.
- 19.
Sriuranpong, V.; Borges, M.W.; Ravi, R.K.; Arnold, D.R.; Nelkin, B.D.; Baylin, S.B.; Ball, D.W. Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res. 2001, 61, 3200–3205.
- 20.
Owen, D.H.; Giffin, M.J.; Bailis, J.M.; Smit, M.D.; Carbone, D.P.; He, K. DLL3: An emerging target in small cell lung cancer. J. Hematol. Oncol. 2019, 12, 61.
- 21.
Ladi, E.; Nichols, J.T.; Ge, W.; Miyamoto, A.; Yao, C.; Yang, L.T.; Boulter, J.; Sun, Y.E.; Kintner, C.; Weinmaster, G. The divergent DSL ligand Dll3 does not activate Notch signaling but cell autonomously attenuates signaling induced by other DSL ligands. J. Cell Biol. 2005, 170, 983–992.
- 22.
Chapman, G.; Sparrow, D.B.; Kremmer, E.; Dunwoodie, S.L. Notch inhibition by the ligand DELTA-LIKE 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis. Hum. Mol. Genet. 2011, 20, 905–916.
- 23.
Sutherland, K.D.; Proost, N.; Brouns, I.; Adriaensen, D.; Song, J.Y.; Berns, A. Cell of origin of small cell lung cancer: Inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell 2011, 19, 754–764.
- 24.
Meder, L.; Konig, K.; Ozretic, L.; Schultheis, A.M.; Ueckeroth, F.; Ade, C.P.; Albus, K.; Boehm, D.; Rommerscheidt-Fuss, U.; Florin, A.; et al. NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas. Int. J. Cancer 2016, 138, 927–938.
- 25.
Saunders, L.R.; Bankovich, A.J.; Anderson, W.C.; Aujay, M.A.; Bheddah, S.; Black, K.; Desai, R.; Escarpe, P.A.; Hampl, J.; Laysang, A.; et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci. Transl. Med. 2015, 7, 302ra136.
- 26.
Sharma, S.K.; Pourat, J.; Abdel-Atti, D.; Carlin, S.D.; Piersigilli, A.; Bankovich, A.J.; Gardner, E.E.; Hamdy, O.; Isse, K.; Bheddah, S.; et al. Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer. Cancer Res. 2017, 77, 3931–3941.
- 27.
Ding, J.; Yeong, C. Advances in DLL3-targeted therapies for small cell lung cancer: Challenges, opportunities, and future directions. Front. Oncol. 2024, 14, 1504139.
- 28.
Saltos, A.; Antonia, S. Breaking the Impasse: Advances in Treatment of Small Cell Lung Cancer. Clin. Chest Med. 2020, 41, 269–280.
- 29.
Isobe, Y.; Sato, K.; Nishinaga, Y.; Takahashi, K.; Taki, S.; Yasui, H.; Shimizu, M.; Endo, R.; Koike, C.; Kuramoto, N.; et al. Near infrared photoimmunotherapy targeting DLL3 for small cell lung cancer. EBioMedicine 2020, 52, 102632.
- 30.
Sato, K.; Choyke, P.L.; Hisataka, K. Selective Cell Elimination from Mixed 3D Culture Using a Near Infrared Photoimmunotherapy Technique. J. Vis. Exp. 2016, 109, 53633.
- 31.
Li, W.Q.; Guo, H.F.; Li, L.Y.; Zhang, Y.F.; Cui, J.W. The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively. Cancer Med. 2021, 10, 4677–4696.
- 32.
Rudin, C.M.; Pietanza, M.C.; Bauer, T.M.; Ready, N.; Morgensztern, D.; Glisson, B.S.; Byers, L.A.; Johnson, M.L.; Burris, H.A., 3rd; Robert, F.; et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: A first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol. 2017, 18, 42–51.
- 33.
Xie, H.; Adjei, A.A. Antibody-Drug Conjugates for the Therapy of Thoracic Malignancies. J. Thorac. Oncol. 2019, 14, 358–376.
- 34.
Morgensztern, D.; Besse, B.; Greillier, L.; Santana-Davila, R.; Ready, N.; Hann, C.L.; Glisson, B.S.; Farago, A.F.; Dowlati, A.; Rudin, C.M.; et al. Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study. Clin. Cancer Res. 2019, 25, 6958–6966.
- 35.
Blackhall, F.; Jao, K.; Greillier, L.; Cho, B.C.; Penkov, K.; Reguart, N.; Majem, M.; Nackaerts, K.; Syrigos, K.; Hansen, K.; et al. Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study. J. Thorac. Oncol. 2021, 16, 1547–1558.
- 36.
Johnson, M.L.; Zvirbule, Z.; Laktionov, K.; Helland, A.; Cho, B.C.; Gutierrez, V.; Colinet, B.; Lena, H.; Wolf, M.; Gottfried, M.; et al. Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study. J. Thorac. Oncol. 2021, 16, 1570–1581.
- 37.
Mullard, A. Cancer stem cell candidate Rova-T discontinued. Nat. Rev. Drug Discov. 2019, 18, 814.
- 38.
Zhou, S.; Liu, M.; Ren, F.; Meng, X.; Yu, J. The landscape of bispecific T cell engager in cancer treatment. Biomark. Res. 2021, 9, 38.
- 39.
Arvedson, T.; Bailis, J.M.; Urbig, T.; Stevens, J.L. Considerations for design, manufacture, and delivery for effective and safe T-cell engager therapies. Curr. Opin. Biotechnol. 2022, 78, 102799.
- 40.
Davila, M.L.; Riviere, I.; Wang, X.; Bartido, S.; Park, J.; Curran, K.; Chung, S.S.; Stefanski, J.; Borquez-Ojeda, O.; Olszewska, M.; et al. Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 2014, 6, 224ra225.
- 41.
Cherkassky, L.; Hou, Z.; Amador-Molina, A.; Adusumilli, P.S. Regional CAR T cell therapy: An ignition key for systemic immunity in solid tumors. Cancer Cell 2022, 40, 569–574.
- 42.
Marofi, F.; Motavalli, R.; Safonov, V.A.; Thangavelu, L.; Yumashev, A.V.; Alexander, M.; Shomali, N.; Chartrand, M.S.; Pathak, Y.; Jarahian, M.; et al. CAR T cells in solid tumors: Challenges and opportunities. Stem Cell Res. Ther. 2021, 12, 81.
- 43.
Zhou, D.; Byers, L.A.; Sable, B.; Smit, M.D.; Sadraei, N.H.; Dutta, S.; Upreti, V.V. Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting Delta-Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC). J. Clin. Pharmacol. 2024, 64, 362–370.
- 44.
Byers, L.A.; Chiappori, A.; Smit, M.-A.D. Phase 1 study of AMG 119, a chimeric antigen receptor (CAR) T cell therapy targeting DLL3, in patients with relapsed/refractory small cell lung cancer (SCLC). J. Clin. Oncol. 2019, 37, TPS8576.
- 45.
Stieglmaier, J.; Benjamin, J.; Nagorsen, D. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer. Expert Opin. Biol. Ther. 2015, 15, 1093–1099.
- 46.
Einsele, H.; Borghaei, H.; Orlowski, R.Z.; Subklewe, M.; Roboz, G.J.; Zugmaier, G.; Kufer, P.; Iskander, K.; Kantarjian, H.M. The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types. Cancer 2020, 126, 3192–3201.
- 47.
Baeuerle, P.A.; Reinhardt, C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2009, 69, 4941–4944.
- 48.
Offner, S.; Hofmeister, R.; Romaniuk, A.; Kufer, P.; Baeuerle, P.A. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol. Immunol. 2006, 43, 763–771.
- 49.
Feldmann, A.; Arndt, C.; Topfer, K.; Stamova, S.; Krone, F.; Cartellieri, M.; Koristka, S.; Michalk, I.; Lindemann, D.; Schmitz, M.; et al. Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T cells. J. Immunol. 2012, 189, 3249–3259.
- 50.
Goebeler, M.E.; Bargou, R. Blinatumomab: A CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy. Leuk. Lymphoma 2016, 57, 1021–1032.
- 51.
Ravandi, F.; Khaldoyanidi, S.; Anderson, A.; Agarwal, S.; Hindoyan, A.; Dai, T.; Vachhani, P.; Bücklein, V.; Ritchie, D.; Wei, A.H.; et al. Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML). Blood 2019, 134, 833.
- 52.
Arvedson, T.; Bailis, J.M.; Britten, C.D.; Klinger, M.; Nagorsen, D.; Coxon, A.; Egen, J.G.; Martin, F. Targeting Solid Tumors with Bispecific T Cell Engager Immune Therapy. Annu. Rev. Cancer Biol. 2022, 6, 17–34.
- 53.
Suurs, F.V.; Lorenczewski, G.; Bailis, J.M.; Stienen, S.; Friedrich, M.; Lee, F.; van der Vegt, B.; de Vries, E.G.E.; de Groot, D.A.; Lub-de Hooge, M.N. Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues. J. Nucl. Med. 2021, 62, 1797–1804.
- 54.
Yang, X.M.; Lin, X.D.; Shi, W.; Xie, S.X.; Huang, X.N.; Yin, S.H.; Jiang, X.B.; Hammock, B.D.; Xu, Z.P.; Lu, X.L. Nanobody-based bispecific T-cell engager (Nb-BiTE): A new platform for enhanced T-cell immunotherapy. Signal Transduct. Target. Ther. 2023, 8, 328.
- 55.
Dolkar, T.; Gates, C.; Hao, Z.; Munker, R. New developments in immunotherapy for SCLC. J. Immunother. Cancer 2025, 13, e009667.
- 56.
Giffin, M.J.; Cooke, K.; Lobenhofer, E.K.; Estrada, J.; Zhan, J.; Deegen, P.; Thomas, M.; Murawsky, C.M.; Werner, J.; Liu, S.; et al. AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer. Clin. Cancer Res. 2021, 27, 1526–1537.
- 57.
Costelloe, C.M.; Chuang, H.H.; Madewell, J.E.; Ueno, N.T. Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST. J. Cancer 2010, 1, 80–92.
- 58.
Paz-Ares, L.; Champiat, S.; Lai, W.V.; Izumi, H.; Govindan, R.; Boyer, M.; Hummel, H.D.; Borghaei, H.; Johnson, M.L.; Steeghs, N.; et al. Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J. Clin. Oncol. 2023, 41, 2893–2903.
- 59.
Hummel, H.D.; Ahn, M.J.; Blackhall, F.; Reck, M.; Akamatsu, H.; Ramalingam, S.S.; Borghaei, H.; Johnson, M.; Dirnberger, F.; Cocks, K.; et al. Patient-Reported Outcomes for Patients with Previously Treated Small Cell Lung Cancer Receiving Tarlatamab: Results from the DeLLphi-301 Phase 2 Trial. Adv. Ther. 2025, 42, 1950–1964.
- 60.
Ahn, M.J.; Cho, B.C.; Felip, E.; Korantzis, I.; Ohashi, K.; Majem, M.; Juan-Vidal, O.; Handzhiev, S.; Izumi, H.; Lee, J.S.; et al. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. N. Engl. J. Med. 2023, 389, 2063–2075.
- 61.
Mountzios, G.; Sun, L.; Cho, B.C.; Demirci, U.; Baka, S.; Gumus, M.; Lugini, A.; Zhu, B.; Yu, Y.; Korantzis, I.; et al. Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy. N. Engl. J. Med. 2025, 393, 349–361.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Suite 4002 Level 4, 447 Collins Street, Melbourne, Victoria 3000, Australia
General Inquiries: info@sciltp.com